Sorafenib (SFB), a multi-kinase inhibitor, is the only approved drug for treating hepatocellular carcinoma (HCC). However, SFB shows low efficacy in many cases. HCC related mortality therefore remains to be high worldwide. SFB, a multi-kinase inhibitor is also known to modulate the redox homeostasis in cancer cells. To understand the effect of SFB on the redox status, a quantitative understanding of the system is necessary. Kinetic modeling of the relevant pathways is a useful approach for obtaining a quantitative understanding of the pathway dynamics and to rank the individual factors based on the extent of influence they wield on the pathway. Here, we report a comprehensive model of the glutathione reaction network (GSH net ), consisting of four modules and includes SFB-induced redox stress. We compared GSH net simulations for HCC of six different etiologies with healthy liver, and correctly identified the expected variations in cancer. Next, we studied alterations induced in the system upon SFB treatment and observed differential H 2 O 2 dynamics in all the conditions. Using metabolic control analysis, we identified glutathione S-transferase (GST) as the enzyme with the highest selective control coefficient, making it an attractive co-target for potentiating the action of SFB across all six etiologies. As a proof-of-concept, we selected ethacrynic acid (EA), a known inhibitor of GST, and verified ex vivo that EA synergistically potentiates the cytotoxic effect of SFB. Being an FDA approved drug, EA is a promising candidate for repurposing as a combination therapy with SFB for HCC treatment.
Introduction
Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, with more than 500 000 known cases, is the second leading cause of cancerrelated deaths worldwide [1] [2] [3] [4] . The highest incidences are in Asia and Africa, and are clearly linked to high prevalence of hepatitis B and C viral infections [3] . Other risk factors of hepatocarcinogenesis are alcoholism, aflatoxin exposure, genetic
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hemochromatosis, a1-antitrypsin deficiency and cryptogenic HCC due to nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) [5] . Sorafenib (SFB), a polypharmacological agent that shows antiproliferative, anti-angiogenic and pro-apoptotic properties, owing to its ability to inhibit Raf-1 and B-Raf kinases, vascular endothelial growth factor receptors 1, 2 and 3 and platelet-derived growth factor receptor b, is the only treatment option available for the advanced stages of liver cancer [6, 7] . By inhibiting these kinases, SFB inhibits cell proliferation and angiogenesis. In earlier stages of HCC, it is used as an adjuvant therapy, either to shrink the tumor prior to surgery or after the surgery to kill any remnant cancer cells. However, SFB treatment provides overall survival benefits of only a few months, and only to a subset of patients (~40%). The treatment outcome depends upon the patient heterogeneity and the liver function status of the patient [8, 9] . Ethnicity-linked variations in SFB efficacy have been observed in the SHARP clinical trial, and also in the Asia-Pacific region trial [7, 10, 11] . Variations in efficacy are also noted in HCCs of different etiologies [5] . Such variations in SFB efficacy are seen in different HCC cell lines as well [12] . While in the longer term, it is important to identify new targets and new drugs to treat HCC, in the shorter term, it would be more advantageous to understand the molecular mechanisms of variation that can be used for deducing rational strategies to enhance the efficacy of SFB. The key enzymes related to SFB metabolism such as CYPs and UGTs exhibit variation in gene expression in cancer, suggesting that SFB metabolism is altered in cancer as compared to normal liver (NL) [13] . Differential metabolism can lead to altered bioavailability in the tumor vicinity and hence contribute to intrinsic resistance [14] . Metabolism of SFB through the CYP3A4 enzyme leads to production of H 2 O 2 that induces oxidative stress [15] , and increases cytotoxicity of the drug. Targeting the redox homeostatic mechanisms have been shown to increase cellular oxidative stress and hence enhancing the killing potential [16, 17] . However, oxidative stress is known to be a doubleedged sword, and it is the balance between various pro-and anti-oxidant factors that defines whether it is beneficial to the cancer cells or the patient [18] . Alterations in redox homeostasis and redox signaling are common features of many cancers. A number of studies suggest that cancer cells experience a higher oxidative stress as compared to their normal counterparts and that a moderate increase in the reactive oxygen species (ROS) level confers a selective advantage to cancer cells and facilitates tumor growth [19] .
However, excess ROS can lead to cell death because of oxidative damage to lipids, proteins and DNA. Thus, a fine balance between the two is essential, and has a major role in deciding the fate of the cell. A quantitative understanding of the system, leading to the generation and metabolism of ROS as well as of SFB is essential to understanding redox homeostasis, and the outcome of treatment with SFB.
Glutathione (GSH), a ubiquitous intracellular tripeptide, interconverts between a reduced and an oxidized form (GSH and GSSG respectively), and functions as one of the primary redox homeostasis generating mechanisms [20] . The two forms, together with other redoxactive molecules in the cell, generate an orchestrated mechanism to maintain the redox potential during the normal functioning of the cell, and modulate it as necessary, upon stress. Thus, the GSH/GSSG ratio is a good indicator of the redox status of the cell. Typically, the GSSG content is < 1% of GSH. GSH turns over rapidly with a half-life of 2-3 h [21, 22] . The biosynthetic pathway of GSH is therefore an important process in the cell, and not surprisingly, is tightly regulated via a negative feedback control mechanism and also by several transcriptional and translational processes [23] . The glutathione metabolism pathway is closely linked with the trans-sulfuration pathway and one-carbon metabolism (1-C metabolism), which in itself is a bicycle consisting of the folate and the methionine cycles [24] . Together, these metabolic pathways form a highly interconnected network (GSH net ) that regulate various biological processes, including nucleotide, protein and lipid metabolism, and also contribute to epigenetic regulation through methylation. By regulating the redox potential of the cell, the GSH net also modulates various signaling processes, such as NF-jB, MAPK, and PI3K signaling [25, 26] . Due to its importance, several enzymes from this pathway have been explored as possible drug targets [27] .
Mathematical modeling has proved to be an essential tool in understanding pathway dynamics in different patho/physiological scenarios [28] [29] [30] [31] . Modeling helps to capture the interplay between different players and facilitates the identification of key points of the pathway that can then be modulated as desired. In this work, we use a quantitative approach to model the human glutathione pathway (GSH net ) in HCC patients and the effect of SFB exposure. We address the following questions -(a) Does the GSH net exhibit any metabolic alterations in HCC? (b) Are such alterations independent of the HCC etiology? (c) Does GSH net exhibit further metabolic remodulation upon SFB treatment? (d) Can we identify putative drug targets that can be used to enhance the cytotoxicity of SFB? To answer all these questions, we first reconstructed a quantitative model of the GSH net that includes 1-C, glutathione and SFB metabolism, for NL and for six different etiologies of HCC. Using these models, we identified flux variations across different conditions. We subsequently performed metabolic control analysis (MCA) and identified potential co-targets that can be explored to potentiate the action of SFB by identifying selective control points. We then tested the hypothesis experimentally using a known inhibitor of the chosen co-target. The experiments provide a proof of principle of the co-targeting strategy ex vivo.
Results
Kinetic models of the GSH net identify metabolic flux variations in HCC of six different etiologies
Generating a normal liver model
The first objective was to reconstruct a model that captures the individual processes in NL required for the glutathione reaction network, which includes (i) the folate cycle, (ii) the methionine cycle, (iii) trans-sulfuration steps and (iv) glutathione biosynthesis-utilization module. Two models related to this were available in literature -the Reed model that contains 60 reactions of 1-C metabolism and trans-sulfuration steps, and the Geenen model which is a simplified version of the Reed model containing 41 reactions, excludes folate cycle, but expands on drug metabolism [32, 33] . We integrated the two models and used the resulting system as the pathway structure for our model (Fig. 1) . GSH net thus contains 73 reactions belonging to four modules (i-iv) described earlier. Detailed information about enzymes including their kinetic parameters, metabolite abundances, and abbreviations are provided in Table S1A,B. The folate cycle, including both cytoplasmic and mitochondrial modules, was captured in 25 ODEs. The methionine cycle (6 ODEs) captures the biosynthesis of S-adenosyl methionine (SAM) from methionine and serves as a source for homocysteine (Hcy) Table S1 . A graphical abstract of whole model is shown in the inset.
production. Hcy links the folate pool, methionine cycle and the trans-sulfuration cycle (Table S1C) . Cysteine is a product of the trans-sulfuration step, and enters glutathione biosynthesis. This is captured in module (iv) of the model, which describes reactions required for glutathione metabolism. The rate parameters for individual reactions were taken from literature and databases for human liver enzymes wherever available (Table S1D) . GST, GPX and GGT enzymes belong to families of multiple members each, and are modeled as previously described [33] . Simulations of the model showed that it reaches a steady-state in the NL and is asymptotically stable.
Model validation
We validated the model in three ways. First, we compared the steady-state concentration of individual metabolites predicted by our model with the data available from primary literature for liver extracts. Table 1 shows that the predicted concentrations of several metabolites from the model, including the folate pool, the GSSG/GSH ratio and the SAM/SAH ratio, are in the same order of magnitude as the metabolite values reported in literature from diverse experiments. This indicates that the model broadly captures the expected metabolic profile of the liver. Second, we compared the glutathione concentration from our predictions with the whole blood metabolomic data available in the HMDB database [34] ( Table 2 ). In this case too, we observed good agreement between the two, further validating the model. Third, we carried out in silico single gene knockouts and compared the effect of the knockout on metabolite abundances with the known metabolic alterations of genetic deficiencies of enzymes reported in the OMIM database [35] . Of the 15 deficiencies tested, our model correctly predicted the phenotype of 13 genetic deficiency diseases (Table S2 ).
Generating HCC-specific models
We then generated HCC models for each of the six etiologies by considering transcriptomic data from tumor tissue samples from HCC patients following liver resections [36] , and comparing with those from NL samples. We used transcriptome data for six different etiologies of HCC [HBV, HCV, alcohol, genetic hemochromatosis (HFE), a-1 antitrypsin deficiency (A1AT) and cryptogenic etiologies]. To understand the commonalities and differences in variations in pathway fluxes across etiologies, we studied each etiology individually. For each enzymatic reaction, we took the fold change in gene expression values for the corresponding gene(s) in HCC with respect to NL, to be proportional to the variation in the corresponding E t (total enzyme) levels (Eqn 2, Materials and methods). Proteomic data of HCC samples are also available for a few of the enzymes in our model [37] . We compared the fold change in protein abundance in HCC with respect to NL (no etiology information is present in the data) with those of the gene expression variations, and find them to be in good agreement, lending additional support to the hypothesis that the gene expression variations used in the model are biologically meaningful (Table S3) .
We simulated the HCC models by solving the ODEs in these conditions, yielding flux profiles of individual reactions for each of the six etiologies. We analyzed the variations due to HCC in the steady-state fluxes of the reactions in the model and also in the steady-state metabolite concentrations, by quantifying the fold change values of all metabolites with respect to NL. Several metabolites showed large variations in all six HCC conditions ( Fig. 2A) . To uncover any similarity in the variations across the six conditions, we applied a hierarchical clustering algorithm (as implemented in MEV software [38] ), and found that five of the etiologies are similar to each other and are in a single cluster.
A1AT shows a different quantitative profile and is considered as an outlier. In all cases including A1AT, we observed an upregulation of glutathione biosynthesis and an increase in the cytoplasmic glutathione levels, indicative of an increased oxidation state in the cancer cells as compared to their normal counterparts, consistent with experimental observations reported earlier [39, 40] . This is illustrated in a metabolite-centric graph ( Fig. 2B ), which shows an increase in flux levels and a concomitant increase in metabolite concentrations pertaining to glutathione metabolism. A timecourse plot of total glutathione (cGSH and cGSSG) levels ( Fig. 2C) shows that it is elevated in all six HCC conditions with a fold change of 1.3-1.7, through the course of the simulation. In the simulations, we also observed a 1.6-fold upregulation of blood glutathione, a~3-fold upregulation of glycine, and a 1.5-fold upregulation of dimethylglycine ( Fig. S1 ) [30] . Concurrently, we observed an average 0.5-fold downregulation of SAM in five (excluding A1AT) conditions. Following the same trend, the SAM/SAH ratios from the simulations were also observed to be downregulated in all HCC models, indicating that HCC exhibits a hypomethylation status in all etiologies [41] ( Fig. S2 ). In A1AT, the SAM levels are~1.6 fold upregulated, while the SAM/SAH ratios are downregulated as in other conditions, indicating a different type of aberration in the methylation status of the cell.
From the simulations, we observed that one carbon metabolism is in general downregulated except for the fluxes for MTHFR, mitochondrial SHMT and GDC (Fig. S3 ). We find that our model correctly captures known tumor-specific changes both at the metabolite level as well as at the enzyme flux level (Table S4) .
SFB treatment leads to perturbation of more than one-third of the GSH net
We then investigated whether SFB, a front-line anticancer drug used widely in the clinic, has any significant influence on the dynamics of the GSH net . For this, we introduced SFB to the model by introducing reactions for its clearance linked to the GSH net , which in essence is a bio-transformation step of SFB to SFB-M2 by CYP3A4 enzyme into the system, a by-product of which is H 2 O 2 [13, 42] . Of all the metabolized forms of SFB, SFB-M2 is one of the most prominent and also a pharmacologically active form [42] . The effect of SFB on the GSH net is primarily due to the release and clearance kinetics of H 2 O 2 . We used a fixed concentration of 5 lM SFB, and dynamically computed H 2 O 2 levels from the simulations. Each simulation was performed for 150 time points, by these time points a steady-state is attained in all cases. The simulations clearly indicated that SFB induces oxidative stress by way of depletion of GSH and accumulation of GSSG, in NL as well as in all the six HCC conditions (Fig. 3A) . Fluxes of GS and GST were seen to be upregulated in the presence of SFB, while the flux through the folate cycle was seen to be downregulated in all conditions. On an average, one-third of the GSH net is perturbed upon SFB exposure (Fig. S4 ). An analysis of H 2 O 2 dynamics revealed that exposure to SFB leads to a rapid production of H 2 O 2 in all conditions (Fig. 3B) . In all the cancer models, H 2 O 2 reached a maximum concentration by~0.7 h, while it takes~1 h in the NL. In addition, in all the cancer models, H 2 O 2 achieves the steady-state concentration earlier (~1.42 h) than the NL (2.1 h). Thus, our simulations clearly indicate that upon SFB exposure, the clearance of H 2 O 2 is more rapid in HCC conditions as compared to NL (Fig. 3B) . GSH/GSSG ratios follow a similar trend, reaching a steady-state in HCC conditions (< 2 h) well before the normal cell (> 2 h), further confirming rapid clearance of oxidative stress in HCC as compared to NL (Fig. 3C) . We observed an average twofold increase in H 2 O 2 concentration in SFB treated-HCC as compared to untreated HCC, while the fold increase in NL due to SFB treatment is 4-fold. This is consistent with multiple experimental studies reported in literature, thus validating the predicted increase in H 2 O 2 upon SFB exposure in HCC [15] . Since the GSH net defines the cellular methylation status, we computed dynamics of SAM/SAH ratios (Fig. S5) as well as the fold change in steady-state level of SAM/SAH ratio and homocysteine (Hcy) concentrations ( Fig. 3D ) in SFB treated condition compared to untreated ones across all conditions. Our model predicted that Hcy concentration would not show any significant difference between SFB treated and untreated conditions at the steady-state. To test this prediction, we experimentally quantified Hcy concentrations in HepG2 cells with and without SFB treatment. Since SFB metabolism mediated by CYP3A4 is known to reach steady-state in 2 h [13] , we choose a conservative time point of 6 h for our experiments. We compare Hcy concentration after SFB treatment to that in untreated cells and find that there is no significant difference between the treated and untreated groups (Fig. 3E ), confirming our prediction. As H 2 O 2 is a negative regulator of the enzyme methionine synthase (MS), SFB treatment leads to inhibition of MS, resulting in accumulation of 5 m-THF metabolite in all conditions, which in turn shuts down other routes of the 1-C cycle.
In summary, upon SFB treatment, glutathione levels decrease, H 2 O 2 levels increase, the folate pool decreases, absolute concentrations of SAM and SAH decrease, but their ratio is maintained.
Metabolic control analysis identifies putative drug targets in HCC
As our ultimate objective is to identify possible intervention points whose manipulation will lead to potentiating the action of SFB, we set out to identify the most controlling points in the GSH net , which when modulated will have the maximum impact on the pathway. MCA is a technique that allows identification of such 'control points' in a systematic manner. MCA in fact has been used several times for this purpose in multiple organisms [43, 44] .
Control points in GSH net upon SFB treatment
We performed MCA using Copasi [45] to understand the global profile of GSH net in the NL and the six HCC conditions. We computed a scaled flux control coefficient (FCC) value from the MCA simulations, whose value ranges between 0 and 1. A value of 1 indicates maximum control over its reaction, while 0 indicates that the particular reaction is controlled completely by some other reaction in the pathway. The sum of all the influences on a particular reaction is always 1. The FCC scores for each reaction in both SFB treated and untreated conditions are provided in Table S5 . We shortlisted the reactions that show an FCC ≥ 0.5 in SFB-treated HCC conditions for further analysis, and computed selectivity indices (Si) for the shortlisted reactions as per Eqn (7). We selected the reactions that show a higher control in SFB-treated HCC as compared to SFB-treated NL (Si > 0.1), as potential selective secondary drug targets, which we refer to as co-targets. Through this selectivity filter, we identified the two highest ranking enzymes, GST and GCS, as co-targets in the SFB-treated condition (Fig. 4A) . Inhibition of either of the co-targets is expected to lead to reduction in clearance of H 2 O 2 , in turn leading to a higher oxidative level in the cancer cell, thereby potentiating the action of SFB.
Overexpression of GST leads to rapid clearance of H 2 O 2 in laboratory evolved SFB-resistant cells
Our simulations so far indicated that the H 2 O 2 buildup will be higher in the SFB treated HCC cells as compared to the untreated HCC cells (Fig. 3A) . Next, we test whether overexpression of GST, a physiologically relevant scenario [46, 47] seen in SFB-resistance, would lead to rapid clearance of H 2 O 2 . Toward this, we incorporated differential gene expression data available in literature for a laboratory evolved SFB-resistant HCC cell line (SFB-R) as compared to a sensitive HepG2 cell line into our GSH net model, thereby rendering it specific to a SFB resistant condition [48] . Nine genes related to GSH net , including GST, were significantly up-regulated in this condition as compared to its SFB-sensitive counterpart, of which four are present in our model. Our simulations indicated that SFB-resistant cells are able to clear H 2 O 2 at a higher rate as compared to the SFB-sensitive cell line, and in fact all other HCC conditions studied here, confirming our predictions (Fig. 4B ). This suggests that the modulation of GSH net via inhibition of GST and GCS may help in reducing the clearance of H 2 O 2, thereby increasing efficacy of SFB.
Primary targets of GSH net in HCC
Given that the GSH net is essential for the normal functioning of the cell, proteins that exert the maximum control on the pathway will also serve as potential primary drug targets, even when it is not coupled with SFB treatment. In such cases where a co-target is also a primary target on its own merit, the combination will have a chance of exhibiting synergy rather than having a mere potentiating role. To find any such primary targets in the GSH net , we applied an independent selectivity filter by computing Si scores for untreated HCC versus untreated NL and find that GST, GCS and GNMT are good primary drug target candidates (Fig. S6) .
A GST inhibitor exhibits synergy with SFB in HepG2 cells
We then proceeded to investigate the effect of inhibiting GST, the top-ranked co-target in SFB treatment and also a primary target on its own merit. Ethacrynic acid (EA), a diuretic drug, is a known inhibitor of human GST and shows an IC50-value in the range of 4-0.3 lM depending on the specific isoform of human GST [49] . It is also known to have anticancer properties [50, 51] . We experimentally tested the effect of EA in combination with SFB in a HepG2 cell line through an MTT assay. We first test the efficacy of SFB and EA individually in HepG2 cells and find that cells are sensitive to both the drugs (Fig. S7) . We observed IC50 for SFB and EA in HepG2 cells to be 7.613 and 25.53 lM, respectively, which clearly indicates that SFB is much more potent than EA. Then, we simultaneously treated HepG2 cells with two concentrations of SFB (1 and 2 lM) and a range of concentrations of EA (5-50 lM) for 48 h and calculated the percentage cell viability and compared it to the viability recorded for the two drugs individually. Using this data, we computed a coefficient of drug interaction (CDI) as described in the Materials and methods section. HepG2 cell viability with SFB alone is shown in Fig. 4C . SFB and EA are clearly seen to be synergistic across a wide concentration range, with a CDI < 0.7, and a maximum synergy of 0.009 at lower (5 lM) concentrations of EA (Fig. 4D) . We tested the effect of the combination in an independent HCC cell line (Huh7) and observed the combination to be synergistic in these cells as well (Fig. S8) .
Discussion
Glutathione is an important metabolite in cancer due to its dual role of ROS in tumorigenesis and modulation of chemotherapy response in patients. Understanding the dynamics of the pathways related to the glutathione reaction network is essential to gain a holistic and quantitative understanding of its impact in cancer. Here, we use a kinetic model capturing these processes (GSH net ) and simulate the model in HCC from six different etiologies. MCA is a robust theoretical framework that describes the systems' properties of a biochemical pathway and rationalizes the control of a given enzyme over the pathway. MCA has been successful in several applications including identification of control points for metabolite overproduction, deciphering the role of transporters in pathway regulation and in drug target identification [43, 44, 52] . Here, we use MCA to identify the most influential steps in the model, and find that GST, GCS and GNMT have the highest levels of control on GSH net . This observation is consistent across all etiologies of HCC. To identify co-targets in GSH net upon SFB treatment, we first incorporated a selectivity filter to identify reactions with increased control in all HCC conditions as compared to NL, when subjected to the same SFB treatment. To identify if some of these co-targets can also serve as primary targets in HCC, we applied a second independent selectivity filter to identify those reactions A combination study in HepG2 cells. Cells were treated with different concentrations of EA ranging from 5 to 50 lM alone or in combination with two concentrations of SFB: 1 and 2 lM for 48 h, after which, cell viability was measured using the MTT assay and compared with the untreated samples. Values are Mean AE SD of data from at least three independent experiments and at least three technical replicates in each. Effect of SFB by itself at 1 and 2 lM concentrations are marked on the y-axis as X1 and X2 respectively. Row CID scores are provided in the inset table for each data point. In all cases, we observed that drugs were significantly synergistic (CDI < 0.7 indicates significant synergistic effect). P-values are calculated by a paired two-tailed t-test, * means significant (P-values between 0.01 and 0.05), ** means very significant (P-values between 0.001 and 0.01), *** means extremely significant (P-values between 0.0001 and 0.001).
that wield at least 10% higher control in untreated HCC as compared to untreated NL (Si (HCC -NL) > 0.1).
In the last two decades, it has been recognized that GST and cGT have higher expression in HCC. This fact has been exploited to selectively target tumor cells with GST-or cGT-activated prodrugs (e.g. TLK286, GSAO and Darinaparsin) in ovarian and nonsmall cell lung cancers [53] . Our results suggest that GST can be co-targeted to potentiate the action of SFB in liver cancer cells. As a proof of concept, we used a known small molecule inhibitor-EA and experimentally inhibited GST in cancer cells in the presence of SFB. The combination is observed to significantly potentiate the cytotoxic effect of SFB on HepG2 and Huh7 cells. EA being an anticancer drug in its own right, albeit less potent than SFB, is observed to be synergistic with SFB over a wide concentration range of each drug, hence validating our computational predictions. Our simulations indicate that GST is a top-ranked co-target for increasing ROS levels in HCC, which can potentiate the action of SFB. As indicated earlier, SFB is much more potent than EA (Fig. S7) . Percentage survival for SFB at low concentrations (1 and 2 lM) is shown in Fig. 4C . At the corresponding concentrations, EA does not show any efficacy, implying it does not have any significant impact on cell survival, again indicating that SFB is more potent. However, when SFB and EA are combined, the potency and efficacy are observed to increase significantly (as compared to the sum of the effect due to each of the drugs individually), indicating synergistic action (CID values in Fig. 4D ).
In an earlier study, we had introduced the concept of target -co-target pairs in the context of drug-resistant bacteria [54] , and subsequently showed that such a strategy was useful in identifying a drug combination for killing drug-resistant Mycobacterium tuberculosis [55, 56] . Co-targets are proteins chosen strategically to be targeted along with a primary target, to enhance the effect of the primary drug. They may not have an effect when inhibited on their own, in which case they have been referred to as ancillary or secondary targets [54] . Although a clear definition for each of these target categories is yet to emerge, in all cases, they refer to being a part of the combination with a primary drug with its own primary target. In all cases, the second target will play an important role in augmenting the function of the first drug, through one or more of the following: auxiliary pharmacodynamic effects, alleviating side effects of the primary drug, improving the bio-availability of the primary drug or modifying the pharmacokinetics of the primary drug and hence its clearance time. Identification of such co-targets poses considerable challenges and requires the knowledge of systems basis of the pharmacological effect of the primary drug. Genome-wide interaction networks have been used for such purposes [57, 58] , which appears to be a promising strategy. However, in several situations, a more quantitative understanding of the system dynamics holds the key to embarking on a rational strategy for co-target identification.
In this work, we use a reasonably comprehensive kinetic model of glutathione reaction network, identify control points through various simulations, and have identified GST as a top-ranked co-target. The advantage of this approach is that, being quantitative, it is a much closer mimic of the biological system being studied, and hence has a higher chance of being successful. This approach too has some drawbacks, the most important of which is that it is limited to a small system, as compared to a genome-wide model. In addition, some assumptions are necessary in model building and simulations, which are (a) the total folate pool is kept constant in the models, (b) the transport reactions are modeled as a consolidated nonenzymatic step and hence cannot be weighted based on the gene expression variations of known transporters, (c) mutations or other alterations in the pathway are not accounted for. Nevertheless, we see that our model has captured the essence of the pathway, showing an increase in glutathione and glycine levels and a downregulation of the SAM/SAH ratio, as described in the validation section.
Different etiological factors are known to affect the host response differently [5] , which is evident from the variations in gene expression patterns in HCC in the six etiological conditions studied here. However, with the exception of A1AT etiology, the other five conditions are fairly similar to each other with respect to the GSH net . Even in A1AT-caused HCC, the trend of gene-expression variation is qualitatively the same as in the other cases, but has a different quantitative profile. Despite this, GST remains as a top-ranked co-target in all cases and hence turns out to be an etiology-independent co-target.
To understand the metabolic adaptations due to SFB treatment, key reactions pertaining to SFB metabolism are incorporated into the model. The primary mode of SFB action is through inhibition of growth related signaling pathways at various steps. However, SFB treated HCC cell cultures are known to experience an oxidative stress, which can augment its cytotoxic effect [15] . Thus, SFB owes its tumor suppression ability to two aspects, perturbation of growth signaling pathways and induction of oxidative stress leading to perturbation in ROS homeostasis. Our simulations indicate that H 2 O 2 levels also accumulate in normal cells upon SFB exposure, which could partially explain its known drug induced cytotoxicity. In addition, our simulations show that HCC cells respond better to oxidative stress upon SFB treatment compared to their normal counterparts.
The effect of SFB on the methylation status of cell is another important aspect. This becomes even more important in the light of various hypomethylating agents such as azacitidine that are currently in the clinical pipeline to increase the efficacy of SFB. Our simulations indicate that SFB treatment does not influence Hcy levels, and hence the methylation status of the cell remains unaltered upon SFB treatment. We experimentally validate this in HepG2 cell lines and show that SFB treatment indeed does not alter the methylation status of the cell, also suggesting that there is no contraindication from this perspective of combining a hypomethylating agent with SFB.
Ethacrynic acid is a drug in current clinical use as a diuretic [59] . Hence, it already has an acceptable safety, pharmacokinetic and bioavailability profile, and can be explored for repurposing. In summary, GST is an attractive target molecule and SFB-EA is a potential new combination that can be explored further in the treatment of HCC.
Materials and methods

Reconstruction of a dynamic model of GSH net
To build tissue and disease specific models of GSH net , a previously published mathematical model of glutathione metabolism in liver [32] was used as a starting point or a base model (Reference BIOMD0000000268). The base model was extended by adding the steps related to general drug detoxification [33] . SFB clearance reactions related to glutathione metabolism were then added to the model [14, 43] . The kinetic parameters of all reactions using Brenda [60] and Sabio-Rk [61] were re-evaluated and modified where necessary (Table S1E ). The rate equations of enzymatic reactions were modeled based on MichaelisMenten kinetics or modified versions thereof, while masskinetics was used to model nonenzymatic reactions. The model was constrained by fixing the concentration of 22 metabolites as reported in the Reed model (2008b), and in HMDB [34] , so as to mimic the human physiological condition more closely. The pharmacokinetics of SFB from multiple phase 1 clinical studies in different cancers, (reviewed in Ref. [62] ), indicated the concentration range of SFB in plasma to be 2.3-10 mgÁmL À1 (which amounts to 4.91-21.51 lM). Furthermore, another clinical trial of the efficacy of SFB in advanced HCC patients has reported the steady-state plasma concentrations of SFB to be in the range of 3.25 to~20 lgÁmL À1 [6] . Based on these, a fixed concentration of 5 lM of SFB was used in all simulations of SFB treatment. A complete list of kinetic equations, parameters of reactions of the kinetic model is provided in Table S1A -G. The model was reconstructed using CELLDE-SIGNER version 4.3 in SBML format. The model simulations were performed using SBML ODE Solver (SOSlib) implemented in CELLDESIGNER [63] , for 100 time points, which was sufficient to reach steady-state for models without SFB treatment. For SFB-treated models, simulations were performed for 150 time units, by this time they reached a steady-state. All models were deposited in BIOMODELS [64] and assigned the identifier MODEL1808060001. To simulate SFB treatment, SFB was added to the model at timezero (at the start of the simulations) in each case. All the models reached a steady-state. As an alternative, a steadystate for each model was first established without SFB treatment and then the same concentration of SFB was introduced. These models also reached a steady-state and no difference in the steady-state values of each metabolite was observed between the two types of simulations. In summary, besides integration of the previous two models, the following are the new contributions to the GSH net model reconstruction: (a) improvisation of the concentrations of fixed metabolites in the model according to the human physiological ranges of metabolites, (b) improvisation of liver-specific kinetic parameters for the 16 enzymes (BHMT, CBS, GNMT, Oxoprolinase, MAT-I, MAT-III, MS, ANPEP, AHCY, SHMT-I, SHMT-II, GGT, GS, GLC, GCT and GT) based on information from current literature, (c) addition of CYP3A4 mediated sorafenib clearance reaction, which is a liver-specific reaction, and (d) addition of explicit gene-protein-reaction associations (GPR associations like in a genome-scale metabolic model), to facilitate incorporation of individual gene-expression or transcriptome or proteome data into the model.
Condition-specific models of GSH net
Expression datasets used for constructing conditionspecific models
The gene expression dataset GSE50579 [37] from GEO [65] was used for this study. It contains 61 clinical samples which include 9 samples for normal and 52 HCC samples with the following etiologies: HBV (n = 8), HCV (n = 9), alcohol (n = 14), cryptogenic (n = 11), genetic hemochromatosis (n = 3), and Alpha-1 antitrypsin deficiency (n = 2). Normalized data were used for computing fold changes. Differentially expressed genes were computed from the normalized dataset and those with a P value ≤ 0.05 were considered to be significantly altered and were integrated into the model. For the remaining genes, a base value of unity was retained in the model. Expression values of genes relevant to the model along with their apparent V max values are in Table S1F ,G.
Integration of gene-expression values
To capture a condition-specific state of GSH net , transcriptome data of the condition was integrated into the model as described in Eqn (2), similar to that reported earlier [31, 66] . Briefly, we assumed that in a disease condition, there is no change in the catalytic activity of enzyme. Alterations in enzyme abundance are considered to render the model specific to the given condition. A condition-specific V max (maximal velocity) was calculated as follows: ðD=NÞ is the fold change in gene-expression of the ith enzyme in the given disease as compared to the normal condition. For GST, GPX and GGT enzymes, the abundance of the most abundant isoenzyme in the liver, was considered for gene-expression integration. Only those DEGs that were statistically significant (P < 0.05) in the cohort were considered. The selected set of DEGs, by definition, occurs in majority of the patients in the dataset, and hence is reflective of the overall sample set in the given data. Nevertheless, to test whether patient heterogeneity is very high and complicates the analysis, individual models for each patient of HCV-HCC were constructed and simulated in exactly the same way. These simulations showed very similar flux profiles, indicating the pathway to be reasonably similar in the cohort. 
Network reconstruction and analysis
To understand the impact of the connectivity patterns in the model, a reaction network was abstracted as a weighted directed metabolite-centric graph, where metabolites are nodes, and reactions leading to their interconversions are the edges. Steady-state concentration of the metabolites form the node weights while fold change (HCC versus normal) of steady-state flux values of the respective enzyme were taken as the edge weights. The network was visualized using CYTOSCAPE [67] .
Sensitivity analysis and differential metabolic control analysis
Metabolic control analysis was performed using the COPASI-4.12.81 software [46] . Briefly, FCC and metabolic control coefficients (MCC) were calculated as follows Flux control coefficient (FCC) :
Metabolic control coefficient (MCC) :
dS dp
To identify putative drug targets in cancer, maximal selectivity was calculated according to [68] . In short, it was assumed that the action of a drug is to decrease the flux of the target enzyme. At this step, only enzyme-catalyzed fluxes showing a positive control coefficient in HCC were selected. 
Experimental validation of model predictions
Reagents, cell line and cell culture SFB was purchased from Santa Cruz, Heidelberg, Germany. EA and 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide (MTT) were obtained from Sigma-Aldrich (St. Louis, MO, USA). About 10 mM stock solution of SFB and EA was prepared in 100% DMSO. Further different concentrations of compounds were prepared by diluting the stock solution in PBS. HepG2 cell line was grown in Dulbecco's Modified Eagle Medium. Media was supplemented with 10% FBS and the penicillin, streptomycin and gentamycin antibiotics. Cells were grown in serum containing growth media until they reached 80-90% confluence, and were later washed thoroughly with 19 PBS and used for experiments.
Homocysteine quantification
Hcy concentration was used to measure the cellular methylation status upon SFB treatment. One million cells were treated with 10 lM SFB for 6 h. After that, Hcy was estimated using Hcy ELISA Kit (YHB1572Hu, Shanghai, China) according to the manufacturer's instructions. Briefly, the cells were subjected to sonication (2 pulse on/off) in cold 80% methanol. The supernatant was obtained by centrifugation at 12 000 g for 5 min. Then, 40 lL supernatant sample was used for the assay. Absorbance at 450 nm was measured in each well. Hcy levels were calculated based on the Hcy standard curve. The total Hcy level was expressed as nM per million cells. Samples were measured in technical duplicate, and blanks without Hcy were used for background correction and assay was performed twice.
Cell viability assay
Cell viability after drug exposure was assessed by the MTT assay. Cells were plated at 5-10 9 10 3 per well in 96-well plates. After completion of treatment with aforementioned drugs, 20 lL of 5 mgÁmL À1 MTT was added in each well, and cells were incubated at 37°C for 2 h. The supernatant was discarded, the precipitate was dissolved in 200 lL DMSO, and plates were read at 570 nm. Results were expressed as percentages of viable cells compared with untreated cells (100% viability).
Drug treatment strategies
For EA and SFB combination studies, 5-10 9 10 3 cells were seeded per well in 96-well plate. After 14 h incubation at 37°C, cells were treated with different concentrations of EA, ranging from (500-5 lM) in 5% serum conditions for 48 h. For testing the combination effect, two concentrations of SFB, 1 lM (at IC 40) and 2 lM (at IC 20), were subsequently added, after which, cell viability was measured using the MTT assay and compared with that of the untreated samples.
Computation of CDI for SFB+EA combination
The CDI was calculated as follows: CDI = AB/(A 9 B) [69, 70] . According to the absorbance of each group, AB formed the ratio of the combination groups to control group; A or B was taken as the ratio of the single agent group to control group. In this case, A was SFB and B was the EA drug. A CDI value < 1, = 1 or > 1 indicates that the pair of drugs are synergistic, additive or antagonistic, respectively. For example, a CDI < 0.7, clearly indicates that the combination has a synergistic effect.
Statistical analysis
Data were expressed as means AE standard error of mean (SEM). Values between groups were compared using the student t-test. A P-value ≤ 0.05 was used for estimating statistical significance. Significance of the data set was calculated using the unpaired t-test in GRAPH PAD-PRISM 5.0 (GraphPad Software, La Jolla, CA, USA). 
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